Latest Asx Companies News

The ASX has suspended trading in six companies starting 1 September 2025 due to late lodgement of mandatory periodic reports. The suspension may be lifted quickly if reports are filed promptly.

Hearts and Minds Investments (HM1) reported a stellar 25.5% pre-tax portfolio return for FY25, outperforming global benchmarks and announcing a raised fully franked dividend of 9.0 cents per share with plans for continued increases.

McMillan Shakespeare Limited reported a 14.1% rise in statutory net profit for FY25, marking the completion of its transformative Simply Stronger program that enhanced digital offerings and customer reach.

BetMakers Technology Group has completed a major transformation in FY25, delivering positive adjusted EBITDA and strong operating cash flow while expanding its global footprint with a strategic US acquisition.

ClearView Wealth Limited reported strong second-half growth in FY25, with underlying NPAT up 11% and life insurance margins rebounding. The company is poised for further expansion in FY26, backed by technology upgrades and strategic simplification.

InvestSMART Group has showcased its position as Australia’s leading direct-to-investor digital wealth platform, reporting $711 million in funds under management and highlighting its integrated ecosystem of low-cost funds, research, and tools.

Invion Limited has disclosed that the US FDA granted Orphan Drug Designation for its lead cancer drug candidate INV043, explaining recent unusual trading activity in its shares. The company confirmed it was unaware of the FDA decision prior to its public release and has now complied with continuous disclosure rules.

Sandon Capital Investments reports a robust 72% increase in net profits, driven by a 32.2% portfolio return that more than doubles market performance, alongside a healthy fully franked dividend yield.

Star Minerals Limited addresses a sharp rise in its share price and trading volume, attributing the movement to pending assay results from recent drilling activities. The company confirms compliance with ASX disclosure rules while preparing to release interpreted data.

Lumos Diagnostics has submitted its CLIA waiver application for FebriDx® to the FDA, backed by strong clinical data and triggering significant milestone payments. Approval could expand the U.S. market opportunity fifteen-fold to over $1 billion.

Miramar Resources has extended its Share Purchase Plan closing date to 27 August 2025, giving shareholders more time to invest at a 20% discount as the company awaits critical exploration results.

Rhythm Biosciences has responded to an ASX price query following a sudden surge in its share price and trading volume, confirming no undisclosed information is driving the activity.